"Deep Knowledge Ventures, a Hong Kong- based venture capital fund that invests in life sciences, cancer research, age-related diseases and regenerative medicine has appointed an artificial intelligence algorithm called VITAL ( Validating Investment Tool for Advancing Life Sciences) to its board of directors."



Klaus Schwab "The Fourth Industrial Revolution", page 149

Deep Knowledge Ventures

Deep Knowledge Analytics

Aging Analytics Agency



“Knowledge” is Power / “Deep Knowledge” is Transcendent Power

Deep Knowledge Ventures is a data-driven investment fund focused on the synergetic convergence of DeepTech, frontier technologies at the nexus of technological megatrends, renowned for its use of sophisticated analytical systems for investment target identification and due-diligence. Major investment sectors include AI, Precision Medicine, Longevity, Blockchain and InvestTech. While it’s major short-term interests are AI and DeepTech, it’s long term vision is focused on Longevity and Precision Health.


The fund values knowledge above profit - a fact that is embedded in its very name and brand. Hence, the fund considers its analytical subsidiaries among its most precious assets, marshalling the fund toward its long-term strategic vision. These two subsidiaries are the analytical engines driving the investment strategy of Deep Knowledge Ventures using sophisticated multi-dimensional analytical frameworks and algorithmic methods that combine hundreds of specially-designed and specifically-weighted metrics and parameters to deliver sophisticated industry analysis, pragmatic forecasting and tangible industry benchmarking.

Screen Shot 2019-07-21 at 9.38.42 PM.png

Deep Knowledge Analytics, the DeepTech-focused analytical subsidiary of Deep Knowledge Ventures,  specializes in conducting special case studies and producing advanced industry analytical reports on the topics of Artificial Intelligence, GovTech, Blockchain, FinTech and Invest-Tech. It has produced a number of comprehensive analytical reports in coordination with the UK All-Parties Parliamentary Groups on AI and on Blockchain, including its AI in UK Landscape Overview 2018 and Blockchain in UK Landscape Overview 2018, unprecedented in their scope and length, and collectively more than 3000 pages. The company has also recently deployed advanced interactive online IT-platforms that feature dynamic mindmaps and filterable, customizable databases updated with new industry developments in real-time.


The Pharma Division of Deep Knowledge Analytics is the leading analytical entity specifically focused on deep intelligence of the pharma industry and the AI for Drug Discovery sector. Its reports have been covered by top-tier tech, business and finance media including Forbes, Financial Times, acknowledged by many other authoritative entities such as MIT Review. Its reports have been recognized by industry experts and executives as the dominant source of sophisticated industry analysis, pragmatic forecasting and tangible benchmarking on the AI in Pharma sector. The Pharma Division of Deep Knowledge Analytics currently serves as the main source of market intelligence and analytics for AI-Pharma, a specialized hybrid hedge fund.


Aging Analytics Agency is the Longevity-focused analytical subsidiary of Deep Knowledge Ventures and the world’s premier provider of public and proprietary industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of Ageing, and the convergence of technologies such as AI and Digital Health and their impact on the healthcare industry. The company provides strategic consulting services in fields related to Longevity, and currently serves as the primary source of analytics for the specialized index hedge fund Longevity.Capital, as well as the UK All-Party Parliamentary Group for Longevity. Whereas previously it was focused on specific sectors of biomedicine industry and scientific/technological domains related to Longevity, in response to beginning to work with several Government-related organizations globally and to recent enhancements to its executive management team (such as the appointment of Eric Kihlstrom, former Director of the UK Government-led £98 Healthy Ageing Industrial Strategy Challenge Fund, as its new director), the agency has begun to focus significant resources to the production of sophisticated open-access and proprietary analytics on the topics of Longevity Governance and Governmental Development Plans (with its most recent report on this topic having been presented in UK Parliament at the APPG for Longevity launch), and to the intersection of Longevity and Advancing Financial Industry of Pension Funds and Insurance Companies, and global multi-trillion opportunity of financial instruments and derivatives related to so-called “Longevity Risk”.


"In May 2014 Deep Knowledge Ventures – a Hong Kong venture-capital firm specialising in regenerative medicine – broke new ground by appointing an algorithm called VITAL to its board. VITAL makes investment recommendations by analysing huge amounts of data on the financial situation, clinical trials and intellectual property of prospective companies. Like the other five board members, the algorithm gets to vote on whether the firm makes an investment in a specific company or not."

Yuval Noah Harari  "Homo Deus: A Brief History of Tomorrow",  page 437

The fund’s long-term strategic vision is driven by the impact investment principles of its Founder and General Partner, Dmitry Kaminskiy, an innovative entrepreneur and investor active in the DeepTech and is a frequent speaker on the topics of AI and Longevity at conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Global Pharmaceutical and Biotechnology Conference”, at the "Precision Medicine World Conference" in Silicon Valley as well as several others at Oxford and Cambridge Universities. He is actively involved in the work of the All-Party Parliamentary Group for Longevity in the UK Parliament, now serving as co-director of the APPG secretariat, overseeing the APPG’s international Longevity cooperation development division and is supervising all of the APPG’s activities related to the concept of establishing Centres of Artificial intelligence for Preventive Medicine and Longevity in the UK.



Deep Knowledge Ventures has presence and activities in Hong Kong, United Kingdom, United States, Switzerland, Canada, and Eastern Europe.


Deep Knowledge Ventures is currently structuring two subsidiary investment funds in the form of hybrid index hedge funds. AI-Pharma will focus on the AI for Drug Discovery sector, applying the fund’s long-standing interests in the AI in Pharma industry (starting with their seed investment into Insilico Medicine in 2014 and culminating in the establishment of the Pharma Division of Deep Knowledge Analytics) to the execution of investment strategies relevant for this highly complex sector. Meanwhile, Longevity.Capital will focus on the leading edge of the Longevity Industry. The fund is applying the analytical methodologies developed by its two analytical subsidiaries to the design and implementation of the new Invest-Tech solutions (novel investment technologies and strategies relevant for the third decade of the twenty-first century), which is the only effective way to implement its long-term strategic vision.